« Back to Record
Citation APA

Van Antwerpen, P., Zouaoui Boudjeltia, K., Legssyer, I., Babar, S., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Neve, J. (2006). Flufenamic acid and its 5-hydroxy-metabolite inhibit the specific oxidation of LDL by the myeloperoxidase/H2O2/CL-system. In Atherosclerosis Supplements: Vol. 7 (p. 524) Elsevier.


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/68470

Van Antwerpen, P., Zouaoui Boudjeltia, K., Legssyer, I., Babar, S., Moreau, P., Moguilevsky, N., Vanhaeverbeek, M., Ducobu, J., & Neve, J. (2006). Flufenamic acid and its 5-hydroxy-metabolite inhibit the specific oxidation of LDL by the myeloperoxidase/H2O2/CL-system. In Atherosclerosis Supplements: Vol. 7 (p. 524) Elsevier.